Navid Navizadeh, MD
Reproductive Endocrinology · Valencia, CANPI 1588654693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 194 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 194 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$653
- Exeltis, USA Inc.$510
- Mayne Pharma Commercial LLC$275
- Agile Therapeutics, Inc.$191
- Bayer$185
- Sumitomo Pharma America, Inc.$184
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,82598%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $653 |
| Exeltis, USA Inc. | 27 | $510 |
| Mayne Pharma Commercial LLC | 13 | $275 |
| Agile Therapeutics, Inc. | 11 | $191 |
| Bayer | 8 | $185 |
| Sumitomo Pharma America, Inc. | 7 | $184 |
| Therapeuticsmd, Inc. | 10 | $181 |
| Hologic Sales And Service, LLC | 8 | $170 |
| Merck | 7 | $138 |
| Astellas Pharma US Inc | 5 | $114 |
| Myovant Sciences Inc. | 7 | $104 |
| Pfizer | 4 | $93 |
| Sage Therapeutics, LLC | 4 | $92 |
| Daiichi Sankyo Inc. | 4 | $90 |
| BD | 4 | $86 |
| Organon | 4 | $78 |
| Coopersurgical, Inc. | 4 | $71 |
| AMAG Pharmaceuticals, Inc. | 4 | $70 |
| Avion Pharmaceuticals | 4 | $59 |
| Scynexis, Inc. | 2 | $56 |
| Dexcom, Inc. | 2 | $41 |
| Baxter Healthcare | 1 | $36 |
| Millicent US Inc | 2 | $36 |
| Shield Therapeutics Inc | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Duchesnay USA Incorporated | 2 | $35 |
| Exact Sciences | 2 | $34 |
| Mission Pharmacal Company | 2 | $32 |
| Vertex | 1 | $28 |
| Smith+Nephew | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Channel Medsystems, Inc. | 1 | $24 |
| Roche Diagnostics Corporation | 1 | $22 |
| Meditrina | 1 | $21 |
| Evofem Biosciences, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Aspira Women's Health Inc | 1 | $18 |
| Biom'up France SAS | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,911 in reported general payments places this provider in the 85th percentile of 230 reproductive endocrinology providers in California.
See all reproductive endocrinology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImvexxyEstradiol | 17 | $6,576 |
| PremarinEstrogens, Conjugated | 13 | $5,830 |
| Estradiol | 113 | $3,969 |
| ProgesteroneProgesterone, Micronized | 41 | $2,177 |
| Estradiol (Twice Weekly)Estradiol | 15 | $1,836 |
| YuvafemEstradiol | 18 | $1,425 |
| DottiEstradiol | 11 | $836 |
| ValacyclovirValacyclovir Hcl | 12 | $541 |
| Medroxyprogesterone Acetate | 14 | $107 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Therapeuticsmd, Inc.Imvexxy | $181 | $6,57617 claims |
| PfizerPremarin | $93 | $5,83013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 230 reproductive endocrinology providers in California.
Other reproductive endocrinology in Valencia
- Sharon WinerBeverly Hills$449K
- Sanjay Agarwalla Jolla$262K
- Valerie FloresSan Diego$184K
- Monica PasternakSan Francisco$77K
- Linda GiudiceSan Francisco$67K
- Valerie BakerSan Jose$66K
- Lisa BechtNewport Beach$48K
- Alexander QuaasSolana Beach$40K
- Shahin GhadirBeverly Hills$31K
- Donna ShoupeLos Angeles$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.